Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Study of Erlotinib in Combination With Bortezomib

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Erlotinib Hydrochloride
Drug: Bortezomib

First Posted Date: 2009-05-08

Last Posted Date: 2015-07-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00895687

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Phase 1

Completed

Conditions: Advanced Cancer, Various, NOS

Interventions: Drug: BMS-833923
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2009-04-20

Last Posted Date: 2016-09-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 27

Registration Number: NCT00884546

Locations: 🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States

and more 4 locations

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

First Posted Date: 2009-04-01

Last Posted Date: 2017-01-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 148

Registration Number: NCT00873093

Locations: 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

and more 168 locations

SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

Phase 2

Terminated

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Mantle-Cell

Interventions: Drug: SCH 727965
Biological: Alemtuzumab
Drug: Bortezomib

First Posted Date: 2009-03-30

Last Posted Date: 2015-08-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 8

Registration Number: NCT00871546

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Phase 2

Terminated

Conditions: Lymphoproliferative Disorder

Interventions: Biological: rituximab
Drug: bortezomib

First Posted Date: 2009-03-26

Last Posted Date: 2017-12-05

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 3

Registration Number: NCT00869323

Locations: 🇺🇸
University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States
🇺🇸
Washington University School of Medicine - Oncology Division, Saint Louis, Missouri, United States

Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: gemcitabine hydrochloride
Other: questionnaire administration

First Posted Date: 2009-03-18

Last Posted Date: 2024-03-20

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 33

Registration Number: NCT00863369

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
South Pasadena Cancer Center, South Pasadena, California, United States